In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans

ABSTRACT The in vitro activities of the new triazole, ravuconazole (BMS-207147), were compared to those of fluconazole and itraconazole against 541 clinical isolates of Cryptococcus neoformans. Isolates were obtained from cerebrospinal fluid (396), blood (116), and miscellaneous clinical specimens (29). Overall, ravuconazole (MIC at which 90% of the isolates are inhibited [MIC90], 0.25 μg/ml) was more active than either itraconazole (MIC90, 0.5 μg/ml) or fluconazole (MIC90, 8 μg/ml). Among the isolates inhibited by ≥16 μg of fluconazole/ml, 90.2% were inhibited by ≤1 μg of ravuconazole/ml. On the basis of our findings and the favorable pharmacokinetic properties of ravuconazole, we suggest that ravuconazole may be useful for the treatment of infectious diseases due to C. neoformans and that further clinical studies to confirm these promising in vitro results are warranted.

[1]  M. Pfaller,et al.  In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America , 1999, Antimicrobial Agents and Chemotherapy.

[2]  J Ramis,et al.  New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. , 1998, Journal of medicinal chemistry.

[3]  A. Tsuruoka,et al.  Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives. , 1998, Chemical & pharmaceutical bulletin.

[4]  M. H. Nguyen,et al.  In Vitro Comparative Efficacy of Voriconazole and Itraconazole against Fluconazole-Susceptible and -Resistant Cryptococcus neoformans Isolates , 1998, Antimicrobial Agents and Chemotherapy.

[5]  D. Bonner,et al.  In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346) , 1998, Antimicrobial Agents and Chemotherapy.

[6]  A. Tsuruoka,et al.  Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. , 1997, Chemical & pharmaceutical bulletin.

[7]  M. Ghannoum,et al.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  K. Katsu,et al.  Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis , 1996, Antimicrobial agents and chemotherapy.

[9]  T. Nakamura,et al.  In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum , 1996, Antimicrobial agents and chemotherapy.

[10]  R. Pinner,et al.  Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group. , 1996, The Journal of infectious diseases.

[11]  M. Ghannoum,et al.  Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole , 1996, Journal of clinical microbiology.

[12]  T. G. Mitchell,et al.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans , 1995, Clinical microbiology reviews.

[13]  H. Waskin,et al.  A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection , 1995 .

[14]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[15]  P. Wayne.  Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved standard-second edition , 2002 .

[16]  M. Ghannoum,et al.  In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. , 1999, Antimicrobial agents and chemotherapy.

[17]  C. Clancy,et al.  The hidden danger of primary fluconazole prophylaxis for patients with AIDS. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  S Ie,et al.  Cryptococcus neoformans. , 1998, The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society.

[19]  R. Pinner,et al.  Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. , 1995, Epidemiologic reviews.